Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:60075 |
Name | estrogen-receptor positive breast cancer |
Definition | A breast cancer that is characterized by the presence of estrogen receptors. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer thoracic cancer breast cancer estrogen-receptor positive breast cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
FGFR1 amp | Dovitinib | estrogen-receptor positive breast cancer | sensitive | detail... |
FGFR1 amp | Cediranib | estrogen-receptor positive breast cancer | sensitive | detail... |
FGFR1 amp | Nintedanib | estrogen-receptor positive breast cancer | sensitive | detail... |
FGFR1 amp | Brivanib | estrogen-receptor positive breast cancer | no benefit | detail... |
PIK3CA E545K | AZD8835 | estrogen-receptor positive breast cancer | sensitive | detail... |
PIK3CA K111N | AZD8835 | estrogen-receptor positive breast cancer | sensitive | detail... |
PIK3CA mutant | AZD8835 | estrogen-receptor positive breast cancer | sensitive | detail... |
PIK3CA mutant | Fulvestrant + Pictilisib | estrogen-receptor positive breast cancer | no benefit | detail... |
PIK3CA mutant | Fulvestrant | estrogen-receptor positive breast cancer | no benefit | detail... |
PIK3CA act mut | Capivasertib + Tamoxifen | estrogen-receptor positive breast cancer | predicted - sensitive | detail... |
PTEN inact mut | Pictilisib | estrogen-receptor positive breast cancer | sensitive | detail... |
PTEN inact mut | Fulvestrant + Pictilisib | estrogen-receptor positive breast cancer | sensitive | detail... |
FGFR1 amp | E7090 | estrogen-receptor positive breast cancer | sensitive | detail... |
PIK3CA E78K PIK3CA E726K PIK3CA D939G | Alpelisib + Letrozole | estrogen-receptor positive breast cancer | no benefit | detail... |
FGFR1 amp | Alpelisib | estrogen-receptor positive breast cancer | resistant | detail... |
FGFR1 amp | Lucitanib | estrogen-receptor positive breast cancer | sensitive | detail... |
FGFR1 over exp PIK3CA mut | Alpelisib + Lucitanib | estrogen-receptor positive breast cancer | sensitive | detail... |
RB1 loss | Palbociclib | estrogen-receptor positive breast cancer | resistant | detail... |
PIK3CA P447_L455del | Alpelisib + Letrozole | estrogen-receptor positive breast cancer | predicted - sensitive | detail... |
PIK3CA mutant | Letrozole | estrogen-receptor positive breast cancer | predicted - sensitive | detail... |
RB1 mutant | Palbociclib | estrogen-receptor positive breast cancer | predicted - resistant | detail... |
TP53 wild-type | KRT-232 | estrogen-receptor positive breast cancer | predicted - sensitive | detail... |
PIK3CA H1047R | Everolimus | estrogen-receptor positive breast cancer | predicted - sensitive | detail... |
PIK3CA act mut | Palbociclib + Taselisib | estrogen-receptor positive breast cancer | predicted - sensitive | detail... |
PIK3CA act mut TSC1 del | Alpelisib | estrogen-receptor positive breast cancer | resistant | detail... |
FGFR1 W4C FGFR1 amp | Lucitanib | estrogen-receptor positive breast cancer | predicted - sensitive | detail... |
ATM LOH ATM inact mut | Ceralasertib + Olaparib | estrogen-receptor positive breast cancer | predicted - sensitive | detail... |
PIK3CA act mut TSC2 del | Alpelisib | estrogen-receptor positive breast cancer | resistant | detail... |
PIK3CA act mut TSC2 del | Taselisib | estrogen-receptor positive breast cancer | resistant | detail... |
PIK3CA act mut TSC1 del | Taselisib | estrogen-receptor positive breast cancer | resistant | detail... |
FGFR1 W4C FGFR1 amp | Rogaratinib | estrogen-receptor positive breast cancer | no benefit | detail... |
FGFR2 M538I | Fexagratinib | estrogen-receptor positive breast cancer | sensitive | detail... |
FGFR2 N550K | Fexagratinib | estrogen-receptor positive breast cancer | sensitive | detail... |
FGFR2 K660N | Fexagratinib | estrogen-receptor positive breast cancer | sensitive | detail... |
FGFR2 M538I | FIIN-2 | estrogen-receptor positive breast cancer | sensitive | detail... |
FGFR2 N550K | FIIN-2 | estrogen-receptor positive breast cancer | sensitive | detail... |
FGFR2 K660N | FIIN-2 | estrogen-receptor positive breast cancer | sensitive | detail... |
FGFR2 M538I | FIIN-3 | estrogen-receptor positive breast cancer | sensitive | detail... |
FGFR2 N550K | FIIN-3 | estrogen-receptor positive breast cancer | sensitive | detail... |
FGFR2 K660N | FIIN-3 | estrogen-receptor positive breast cancer | sensitive | detail... |
FGFR2 M538I | Trametinib | estrogen-receptor positive breast cancer | sensitive | detail... |
FGFR2 N550K | Trametinib | estrogen-receptor positive breast cancer | sensitive | detail... |
FGFR2 K660N | Trametinib | estrogen-receptor positive breast cancer | sensitive | detail... |
FGFR2 M538I | SHP099 | estrogen-receptor positive breast cancer | sensitive | detail... |
FGFR2 N550K | SHP099 | estrogen-receptor positive breast cancer | sensitive | detail... |
FGFR2 K660N | SHP099 | estrogen-receptor positive breast cancer | sensitive | detail... |
PIK3CA E545K | Alpelisib + Everolimus | estrogen-receptor positive breast cancer | predicted - sensitive | detail... |
PIK3CA E545K | Afatinib + Alpelisib | estrogen-receptor positive breast cancer | predicted - sensitive | detail... |
PIK3CA H1047R | Alpelisib + Everolimus | estrogen-receptor positive breast cancer | predicted - sensitive | detail... |
PIK3CA H1047R | Afatinib + Alpelisib | estrogen-receptor positive breast cancer | predicted - sensitive | detail... |
PIK3CA E545K | AZD4573 + Palbociclib | estrogen-receptor positive breast cancer | sensitive | detail... |
PIK3CA E453K PIK3CA H1047R | RLY-2608 | estrogen-receptor positive breast cancer | predicted - sensitive | detail... |
PIK3CA E542K | RLY-2608 | estrogen-receptor positive breast cancer | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00570323 | Phase II | Anastrozole + Fulvestrant Anastrozole | Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer | Completed | USA | 0 |
NCT00759642 | Phase II | Lapatinib | Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy | Terminated | USA | 0 |
NCT01027416 | Phase I | Tamoxifen | Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients | Completed | USA | 0 |
NCT01177397 | Phase Ib/II | Onatasertib | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | Completed | USA | GBR | FRA | ESP | 0 |
NCT01219699 | Phase I | Alpelisib Alpelisib + Fulvestrant | A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene | Completed | USA | NLD | GBR | ESP | DEU | 0 |
NCT01587703 | Phase I | Molibresib | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers | Completed | USA | NLD | GBR | FRA | ESP | AUS | 1 |
NCT01594216 | Phase II | Exemestane + Ruxolitinib | Ruxolitinib in Estrogen Receptor Positive Breast Cancer | Completed | USA | 0 |
NCT01857193 | Phase Ib/II | Everolimus + Exemestane + Ribociclib Exemestane + Ribociclib | Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer | Completed | USA | FRA | ESP | BEL | 1 |
NCT01872260 | Phase I | Alpelisib + Letrozole Alpelisib + Letrozole + Ribociclib Letrozole + Ribociclib | Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer | Active, not recruiting | USA | ITA | GBR | FRA | ESP | CHE | AUS | 1 |
NCT01990209 | Phase II | Orteronel | Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) | Completed | USA | 0 |
NCT02035813 | Phase II | Ribociclib Eribulin | DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs). | Completed | DEU | 0 |
NCT02049957 | Phase Ib/II | Fulvestrant + Sapanisertib Exemestane + Sapanisertib | Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer | Completed | USA | FRA | BEL | 0 |
NCT02115282 | Phase III | Exemestane + Goserelin Entinostat + Exemestane + Goserelin | Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic | Active, not recruiting | USA | 1 |
NCT02219789 | Phase I | Fulvestrant Alisertib | Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT02229084 | Phase Ib/II | Montanide ISA 51 + P10s-PADRE P10s-PADRE | Vaccination of High Risk Breast Cancer Patients | Completed | USA | 0 |
NCT02308020 | Phase II | Abemaciclib | A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain | Completed | USA | ITA | ISR | FRA | ESP | CAN | BEL | AUT | AUS | 0 |
NCT02340221 | Phase III | Fulvestrant + Taselisib Fulvestrant | A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy (SANDPIPER) | Terminated | USA | TUR | SWE | ROU | POL | NLD | ITA | GRC | FRA | FIN | ESP | DEU | CZE | CAN | BGR | AUT | AUS | 11 |
NCT02395627 | Phase II | Pembrolizumab + Tamoxifen + Vorinostat | Reversing Hormone Therapy Resistance With Epigenetic-Immune Modification | Terminated | USA | 0 |
NCT02569801 | Phase II | GDC-0810 Fulvestrant | A Study of GDC-0810 Versus Fulvestrant in Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy | Terminated | USA | GBR | ESP | DEU | AUS | 1 |
NCT02580448 | Phase Ib/II | Seviteronel | A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer | Completed | USA | 0 |
NCT02598557 | Phase II | Exemestane | Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer | Completed | USA | ITA | 0 |
NCT02599714 | Phase Ib/II | Fulvestrant + Palbociclib + Vistusertib | Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (PASTOR) | Completed | USA | GBR | 0 |
NCT02676986 | Phase II | Enzalutamide + Exemestane Exemestane Enzalutamide | Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer (ARB) | Completed | USA | IRL | GBR | ESP | DEU | 0 |
NCT02734615 | Phase I | Alpelisib + LSZ 102 LSZ 102 + Ribociclib LSZ 102 | Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers | Terminated | USA | ITA | FRA | DEU | BEL | 2 |
NCT02783300 | Phase I | GSK3326595 | Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) | Completed | USA | NLD | FRA | CAN | 0 |
NCT02820961 | Phase I | Entinostat + Exemestane | Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer | Completed | USA | 0 |
NCT02913430 | Phase II | Fulvestrant + Palbociclib Palbociclib + Tamoxifen | Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib | Completed | USA | 0 |
NCT02918084 | Phase III | Exemestane Anastrozole Letrozole | CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer (GIM10-CONSENT) | Active, not recruiting | ITA | 0 |
NCT02988986 | Phase II | Sapanisertib + Tamoxifen | TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer | Completed | USA | 0 |
NCT03092635 | Phase I | Metformin + OPC | AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy | Terminated | USA | 0 |
NCT03201913 | Phase I | TTC-352 | Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy | Completed | USA | 0 |
NCT03285412 | Phase II | Ribociclib | CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer (LEADER) | Recruiting | USA | 0 |
NCT03289039 | Phase II | Neratinib Fulvestrant + Neratinib | Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer | Terminated | USA | 0 |
NCT03321981 | Phase II | Letrozole + Zenocutuzumab Anastrozole + Zenocutuzumab Fulvestrant + Zenocutuzumab Exemestane + Zenocutuzumab Trastuzumab + Zenocutuzumab Trastuzumab + Vinorelbine + Zenocutuzumab | MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer | Completed | USA | NLD | GBR | FRA | ESP | BEL | 1 |
NCT03330405 | Phase II | Avelumab + Talazoparib | Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors | Terminated | USA | HUN | GBR | DNK | CAN | BEL | AUS | 2 |
NCT03361800 | Phase I | Entinostat | Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC | Terminated | USA | 0 |
NCT03573648 | Phase II | Leuprolide Avelumab + Palbociclib + Tamoxifen Avelumab + Tamoxifen Leuprolide + Palbociclib Avelumab + Leuprolide Avelumab + Leuprolide + Palbociclib Tamoxifen Goserelin Palbociclib + Tamoxifen Avelumab + Goserelin Goserelin + Palbociclib Avelumab + Goserelin + Palbociclib | Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (ImmunoADAPT) | Active, not recruiting | USA | 0 |
NCT03584009 | Phase II | Fulvestrant Fulvestrant + Venetoclax | A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy | Terminated | USA | GBR | DEU | CAN | AUS | 0 |
NCT03733990 | Phase Ib/II | FP-1305 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Completed | USA | NLD | GBR | FRA | FIN | ESP | 0 |
NCT03874325 | Phase II | Durvalumab + Exemestane Durvalumab + Letrozole Anastrozole + Durvalumab | Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer | Terminated | USA | 0 |
NCT03900884 | Phase I | Letrozole + Palbociclib + Venetoclax | Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer (PALVEN) | Active, not recruiting | AUS | 0 |
NCT04054752 | Phase I | NT-I7 | Vaccine Response With NT-I7 | Withdrawn | USA | 0 |
NCT04109066 | Phase III | Paclitaxel Anthracycline + Cyclophosphamide + Nivolumab Nivolumab + Paclitaxel | Study of Nivolumab Versus Placebo in Participants With High-Risk Breast Cancer (CheckMate 7FL) | Completed | USA | TUR | ROU | POL | NLD | ITA | IRL | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 11 |
NCT04190056 | Phase II | Pembrolizumab + Tamoxifen Pembrolizumab + Tamoxifen + Vorinostat | Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer | Terminated | USA | 0 |
NCT04197999 | Phase I | GMI-1359 | A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer | Terminated | USA | 0 |
NCT04256941 | Phase II | Abemaciclib + Fulvestrant Fulvestrant + Palbociclib Letrozole + Palbociclib Fulvestrant + Ribociclib Abemaciclib + Letrozole Anastrozole + Palbociclib Anastrozole + Ribociclib Letrozole + Ribociclib Abemaciclib + Anastrozole | Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study | Completed | USA | 0 |
NCT04305834 | Phase II | Abemaciclib | Abemaciclib Monotherapy in Treating Older Patients With Hormone Receptor Positive Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT04478279 | Phase Ib/II | ST-101 | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | GBR | 0 |
NCT04557449 | Phase I | Letrozole + PF-07220060 Fulvestrant + PF-07220060 PF-07220060 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i) | Recruiting | USA | SVK | GBR | CZE | ARG | 3 |
NCT04601116 | Phase III | Atorvastatin | The MASTER Study (MAmmary Cancer STatin ER Positive Study) | Recruiting | DNK | 0 |
NCT04682431 | Phase I | Pembrolizumab + PY159 PY159 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04706962 | Phase I | TH1902 | TH1902 in Patients With Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT04789668 | Phase Ib/II | Bintrafusp alfa + Pimasertib | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | Completed | USA | 0 |
NCT04802759 | Phase Ib/II | Abemaciclib + Giredestrant Giredestrant + Ipatasertib Giredestrant Everolimus + Giredestrant Giredestrant + Inavolisib Giredestrant + Ribociclib | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer | Recruiting | USA | ISR | ESP | AUS | 1 |
NCT05020860 | Phase II | Cyclophosphamide + Doxorubicin + Paclitaxel Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab | Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer (RESPONSE) | Recruiting | USA | 0 |
NCT05538572 | Phase I | PRT3645 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | Completed | USA | 1 |
NCT05565417 | Phase Ib/II | IMT-009 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | Recruiting | USA | 0 |
NCT05601440 | Phase II | Gemcitabine + RP-6306 Fulvestrant + Niraparib | Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer | Recruiting | CAN | 0 |
NCT05627960 | Phase I | AG01 | First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT05642949 | Phase Ib/II | MHB036C | Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05696626 | Phase III | Abemaciclib + Fulvestrant Abemaciclib + Lasofoxifene | Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEIII) | Recruiting | USA | TUR | ROU | POL | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUS | 3 |
NCT05703555 | Phase II | SAR408701 | INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701 (INTRUSION) | Withdrawn | NLD | 0 |
NCT05720117 | Phase I | PYX-201 | Study of PYX-201 in Solid Tumors | Recruiting | USA | ESP | BEL | 0 |
NCT05933395 | Phase II | Abemaciclib + Fulvestrant Fulvestrant + Neratinib Alpelisib + Fulvestrant Everolimus + Fulvestrant | Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor (GERTRUDE) | Recruiting | USA | 0 |
NCT06018337 | Phase III | Nab-paclitaxel Paclitaxel DB-1303 Capecitabine | A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) | Recruiting | USA | POL | ITA | HUN | GBR | FRA | CAN | BEL | AUS | 3 |
NCT06026657 | Phase Ib/II | Gemcitabine + TGF-beta-imprinted NK cells Gemcitabine + Naxitamab + TGF-beta-imprinted NK cells | Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFbeta-i Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer | Recruiting | USA | 0 |
NCT06224673 | Phase II | ARX-788 | ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer | Not yet recruiting | USA | 0 |
NCT06263543 | Phase II | Sacituzumab govitecan-hziy | Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC (SERIES) | Recruiting | USA | 0 |
NCT06545331 | Phase I | Pembrolizumab + XB010 XB010 | Study of XB010 in Subjects With Solid Tumors | Recruiting | USA | 0 |
NCT06680596 | Phase II | Trastuzumab deruxtecan | Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy (SAFIR3LibHERty) | Not yet recruiting | FRA | 0 |